Painful Non-Diabetic Lumbosacral Radiculoplexus Neuropathy Following Tirzepatide Exposure: A Case Report.
Background and purpose
Lumbosacral radiculoplexus neuropathy (LRPN) is an uncommon neuropathic syndrome occurring predominantly in patients with diabetes mellitus, although non-diabetic forms are increasingly recognized. Rare peripheral neuropathies have been reported during glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist [GLP-1RA]) therapy; however, LRPN has not previously been described in this clinical context, particularly in non-diabetic individuals. We describe a well-characterized case of painful non-diabetic LRPN developing following a period of rapid metabolic shift during tirzepatide therapy.
Case presentation
A 62-year-old man previously treated with tirzepatide for weight loss developed, approximately 8 weeks after discontinuation, acute left-sided low back pain, rapidly progressing to severe neuropathic pain, distal weakness, and sensory loss. MR neurography demonstrated enlargement and contrast enhancement of the left L5 nerve root and sciatic nerve, associated with denervation edema. Electrophysiological studies demonstrated an axonal process consistent with lumbosacral radiculoplexus neuropathy, while cerebrospinal fluid analysis showed albuminocytological dissociation. Classical diabetic-related plexopathy was excluded by normal glucose values; an extensive work-up excluded infectious, neoplastic, paraneoplastic, and systemic inflammatory causes.
Treatment and outcome
The patient was treated with intravenous methylprednisolone followed by an oral corticosteroid taper and intensive rehabilitation. At 8-month follow-up, neuropathic pain had completely resolved and plantar flexion had recovered, whereas severe foot dorsiflexion weakness persisted, and the patient walked with a single crutch and an ankle-foot orthosis, consistent with the expected outcome of severe axonal lumbosacral radiculoplexus neuropathy.
Discussion and conclusions
Tirzepatide exposure was associated with rapid weight loss in a normoglycaemic individual. This case highlights a severe non-diabetic lumbosacral radiculoplexus neuropathy following a period of rapid metabolic shift during GLP-1RA therapy. Although causality cannot be established, the temporal association and clinical context raise the hypothesis that abrupt metabolic changes may act as a permissive factor for immune-mediated lumbosacral plexus injury in susceptible individuals.
Keywords
GLP‐1 receptor agonists, lumbosacral radiculoplexus neuropathy, metabolic shift, non‐diabetic neuropathy, peripheral neuropathy, tirzepatide

Comments
Sign in to join the conversation.
Sign in to commentNo comments yet. Be the first to share your thoughts.